Summary
Acute Myeloid Leukemia (AML) and the Need for Advanced Treatment: AML is a prevalent hematological malignancy in adults, with a 5-year survival rate of only 32%. While approximately 32,000 AML patients are diagnosed annually in the US today, projections suggest this will rise to 36,000 by 2027. Current treatments, such as allogeneic bone marrow transplantation, have limited applicability due to high morbidity and treatment- associated mortality. The Problem of Immune Evasion: AML cells employ immune evasion tactics, notably up-regulation of co- inhibitory ligands like Vasoactive Intestinal Pep
